Authors

Derek Choy is Co-founder and Chief Product Officer of Aktana

Future-Proofing CRM Investments in Life Sciences: Observations from Dreamforce 2024

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

Partha Anbil

Senior advisor to NextGen Invent Corporation

Measuring the ROI of SPP Adherence Programs

3 months ago

Can deeper data from specialty pharmacy providers bolster both patient outcomes and financial returns?

Kenneth Getz, MBA

Executive Director of the Tufts Center for the Study of Drug Development (CSDD)

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

a year ago

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Authors

Future-Proofing CRM Investments in Life Sciences: Observations from Dreamforce 2024

Measuring the ROI of SPP Adherence Programs

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Trending on PharmExec

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships